Immunomic Therapeutics is launching an incubator and looking for one lucky startup

Immunomic Therapeutics signed a $315 million licensing deal with a Japanese pharmaceutical company last year.
Now the company is looking to help another Maryland biotech startup get off the ground.
The Rockville-based company is accepting applications for its Cancer Discovery Incubator through Dec. 31.
Apply
The award is offering a company a $10,000/month stipend, bench space and supplies to conduct proof-of-concept experiments. Immumonic leaders William Hearl and Teri Heiland will also provide mentorship. The company is partnering with BioHealth Innovation on the effort.
The application process includes an initial screening and pitch day, and is set to be complete by February 2017.
Immunomic developed a vaccine for allergies based on research by Johns Hopkins University professor Tom August. The company signed the licensing deal with Astellas Pharma last year, and is also looking to set its sights on cancer.
“It is exciting to pay it forward and empower a new innovator to work in Maryland and conduct proof-of-concept experiments and ultimately, attract funding, partnerships, and fuel growth,” Herl said in a statement.